Regulation of ω-3 fish oil emulsion on the SIRS during the initial stage of severe acute pancreatitis

Abstract

The aim of this study was to explore the effects of parenteral supplementation with ω-3 fish oil emulsion (Omegaven®) on systemic inflammatory response syndrome (SIRS) during the initial stage of severe acute pancreatitis (SAP). In a prospective, randomized and controlled trial, 60 patients with SAP were randomized either to treat with conventional therapy (Con group, n=30) or conventional therapy plus intravenous supplementation with ω-3 fish oil emulsion 0.2 g/kg every day (FO group, n=30). The effects were analyzed by the SIRS-related indexes. The results showed that APACHE-II scores in FO group were significantly lower, and the gap increased much farther after the 4th day than those in Con group (P<0.05). Fluid equilibrium time became shorter markedly in FO group than in Con group (5.1±2.2 days vs 8.4±2.3 days). In FO group, SIRS scores were markedly decreased and the SIRS state vanished after the 4th day; Plasma level of TNF-α was significantly reduced, while IL-10 decreased markedly, most prominently between the 4th and 7th day, and the ratio of IL-10/TNF-α raised as compared with Con group (P<0.05). During the initial stage of SAP, parenteral supplementation with ω-3 fish oil emulsion could efficiently lower the magnitude and persistence time of the SIRS, markedly retrieve the unbalance of the pro-/anti-inflammatory cytokines, improve severe condition of illness and may provide a new way to regulate the SIRS.

Keywords

severe acute pancreatitis / systemic inflammatory response syndrome / ω-3 fish oil emulsion / pro-/anti-inflammatory cytokines / parenteral supplementation

References

[1] CalderP.C.. N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr, 2006, 83(6Suppl1505S-1519S

[2] BradleyE.L.3rd. A clinically based classification system for acute pancreatitis: summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga., September 11 through 13, 1992. Arch Surg, 1993, 128(5): 586-590

[3] IshikawaK., IdoguchiK., TanakaH., et al. . Classification of acute pancreatitis based on retroperitoneal extension: Application of the concept of interfascial planes. European Journal of Radiology, 2006, 60(3): 445-452

[4] MitchellR.M., ByrneM.F., BaillieJ.. Pancreatitis. Lancet, 2003, 361(9367): 1447-1455

[5] American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Crit Care Med, 1992, 20(6): 864-874

[6] BandS., SinghP., PooranN., et al. . Evaluation of factors that have reduced mortality form acute pancreatitis over the past 20 years. J Clin Gastroenteroi, 2002, 35(1): 50

[7] WangC.Y.. Some important aspects to refine further the treatment of severe acute pancreatitis. Clin J Surg (Chinese), 2006, 11(6): 11-13

[8] RAU BettinaM.. Outcome determinants in acute pancreatitis. Am J Surg, 2007, 194(4Suppl): S39-S44

[9] WangC.Y., ZhaoG., ZhangW.K., et al. . Therapeutic effect and mechanism of ulinastatin on severe acute pancreatitis. Clin J Surg (China), 2000, 8(3): 172

[10] ZhouF., WangC.Y., WangC.D., et al. . Clinical observation of prostaglandin E1 on organ protection in severe acute pancreatitis. Clin J Surg (Chinese), 2004, 12(9): 540-541

[11] ZhangX.P., ZhangL., ChenL.J., et al. . Influence of dexamethasone on inflammatory mediators and NF-κB expression in multiple organs of rats with severe acute pancreatitis. World J Gastroenterol, 2007, 13(4): 548-556

[12] ZhangX.P., ZhangL., WangY., et al. . Study of the Protective Effects of Dexamethasone on Multiple Organ Injury in Rats with Severe Acute Pancreatitis. JOP, 2007, 8(4): 400-412

[13] GaoY.B., WangX.S., LiuW., et al. . Effect of preventing cell Ca²⁺ overload on cytokines in severe acute pancreatitis. J Clin Res, 2007, 24(7): 1074-1075

[14] MayerK., SchaeferM.B., SeegerW.. Fish oil in the critically ill: from experimental to clinical data. Curr Opin Clin Nutr Metab Care, 2006, 9(2): 140-148

[15] NakamuraK., KariyazonoH., KomokataT., et al. . Influence of preoperative administration of ω-3 fatty acid-enriched supplement on inflammatory and immune responses in patients undergoing major surgery for cancer. Nutrition, 2005, 21(6): 639-649

[16] HellerA.R., RosslerS., LitzR.J., et al. . Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med, 2006, 34(4): 972-979

[17] StehrS.N., HellerA.R.. Omega-3 fatty acid effects on biochemical indices following cancer surgery. Clin Chim Acta, 2006, 373(1–2): 1-8

[18] FlintR., WindsorJ.A.. Early Physiological Response to Intensive Care as a Clinically Relevant Approach to Predicting the Outcome in Severe Acute Pancreatitis. Arch Surg., 2004, 139(4): 438-443

[19] VasilescuC., ButtenschoenK., OlteanuM., et al. . Severe acute pancreatitis between systematic inflammatory response syndrome and sepsis: insights from a mathematical model of endotoxin tolerance. Am J Surg, 2007, 194(4Suppl): S33-S38

[20] WeissG., MeyerF., MatthiesB., et al. . Immunomodulation by perioperative administration of n-3 fatty acids. Br J Nutr, 2002, 87(Suppl1): S89-S94

[21] TsekosE., ReuterC., StehleP., et al. . Perioperative administration of parenteral fish oil supplements in a routine clinical setting improves patient outcome after major abdominal surgery. Clin Nutr, 2004, 23(3): 325-330